Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension

Advances in Therapy

Volumn 28, Issue 7, 2011, Pages 575-585

  Erb, Carl ^a   Lanzl, Ines ^b   Seidova, Seid Fatima ^b   Kimmich, Friedemann ^c  

^a Klinik am Wittenbergplatz   (Germany)

^b Private Practice   (Germany)

^c Eyecons   (Germany)

Author keywords

Glaucoma; Ocular hypertension; Ocular surface disease; Preservatives; Prostaglandin analogs; Tafluprost

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; LEUPRORELIN; PRESERVATIVE FREE TAFLUPROST; PROSTAGLANDIN DERIVATIVE; SAFLUTAN; TAFLUPROST; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALGORITHM; ALLERGY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ETHNIC GROUP; FEMALE; GERMAN; GLAUCOMA; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; PATIENT SATISFACTION; PATIENT SELECTION; PROSPECTIVE STUDY; PRURITUS; RATING SCALE; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; FEMALE; GERMANY; GLAUCOMA; HUMANS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PRESERVATIVES, PHARMACEUTICAL; PROSTAGLANDINS F; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82455162408     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0038-9     Document Type: Review

References (25)

1. Quigley HA, Broman AT. The number of peoplewith glaucoma worldwide in 2010 and 2020. Br JOphthalmol. 2006;90: 262-267. (Pubitemid 43325451)
2. Leske MC, Heijl A, Hussein M, et al. Factors forglaucoma progression and the effect of treatment: The Early Manifest Glaucoma Treatment Trial. Arch Ophthalmol. 2003;121: 48-56. (Pubitemid 36401765)
3. AGIS Investigators. The Advanced GlaucomaIntervention Study (AGIS): 7. The relationshipbetween control of intraocular pressure andvisual field deterioration. Am J Ophthalmol.2000;130: 429-440.
4. Heijl, A, Leske, MC, Bengtsson, B, et al. Reductionof intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial.Arch Ophthalmol. 2002;120: 1268-1279. (Pubitemid 36105431)
5. Collaborative Normal-Tension Glaucoma StudyGroup. Comparison of glaucomatous progressionbetween untreated patients with normal-tensionglaucoma and patients with therapeuticallyreduced intraocular pressures. Am J Ophthalmol.1998;126: 487-497.
6. Kass, MA, Heuer, DK, Higginbotham, EJ, et al.The Ocular Hypertension Treatment Study: Arandomized trial determines that topical ocularhypotensive medication delays or prevents theonset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120: 701-713. (Pubitemid 34620348)
7. Bean GW, Camras CB. Commercially availableprostaglandin analogs for the reduction ofintraocular pressure: Similarities and differences.Surv Ophthalmol. 2008; 53(Suppl. 1): S69-S84.
8. Takagi Y, Nakajima T, Shimazaki A, et al.Pharmacological characteristics of AFP-168(tafluprost), a new prostanoid FP receptor agonist,as an ocular hypotensive drug. Exp. Eye Res.2004;78: 767-776. (Pubitemid 38252953)
9. Traverso CE, Ropo A, Papadia M, et al. A phaseII study on the duration and stability of theintraocular pressure-lowering effect and tolerabilityof tafluprost compared with latanoprost. J OculPharmacol Ther. 2010;26: 97-104.
10. Hamacher T, Airaksinen J, Saarela V, LiinamaaMJ, Richter U, Ropo A. Efficacy and safety levelsof preserved and preservative-free tafluprost areequivalent in patients with glaucoma or ocularhypertension: Results from a pharmacodynamicsanalysis. Acta Ophthalmol Suppl (Oxf).2008;242: 14-19.
11. Uusitalo H, Pillunat LE, Ropo A, et al. Efficacy andsafety of tafluprost 0.0015% versus latanoprost0.005% eye drops in open-angle glaucoma andocular hypertension: 24-month results of arandomized, double-masked phase III study. Acta Ophthalmol. 2010;88: 12-19.
12. Baudouin C. Side effects of antiglaucomatous drugson the ocular surface. Curr Opin Ophthalmol.1996;7: 80-86. (Pubitemid 26268834)
13. Brasnu E, Brignole-Baudouin F, Riancho L,Guenoun JM, Warnet JM, Baudouin C. In vitroeffects of preservative-free tafluprost and preservedlatanoprost, travoprost, and bimatoprost in aconjunctival epithelial cell line. Curr Eye Res.2008;33: 303-312. (Pubitemid 351507760)
14. Martone, G, Frezzotti P, Tosi GM et al. An in vivoconfocal microscopy analysis of effects of topicalantiglaucoma therapy with preservative on cornealinnervation and morphology. Am J Ophthalmol.2009;147: 725-735.
15. Vaede D, Caudouin C, Warnet JM, et al.Preservatives in eyedrops: Toward awareness oftheir toxicity. J Fr Ophthalmol. 2010;33: 505-524.
16. Baudoin C. Mechanisms of failure inglaucoma filtering surgery: A consequence ofantiglaucomatous drugs? Int J Clin Pharmacol Res.1996;16: 29-41.
17. Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: Thegood, the bad and the ugly. Prog. Retin Eye Res.2010;29: 312-334.
18. Erb C, Gast U, Schremmer D. German register forglaucoma patients with dry eye. I. Basic outcomewith respect to dry eye. Graefes Arch Clin ExpOphthalmol. 2008;246: 1593-601.
19. Leung EW, Kedeiros FA, Weinreb RN. Prevalenceof ocular surface disease in glaucoma patients. JGlaucoma. 2008;17: 350-355.
20. Rossi GC, Tinelli C, Pasinetti GM, et al. Dry eyesyndrome-related quality of life in glaucomapatients. Eur J Ophthalmol. 2009;19: 572-579.
21. Fechtner RD, Godfrey DG, Budenz D, et al.Prevalence of ocular surface complaints in patientswith glaucoma using topical intraocular pressureloweringmedications. Cornea. 2010;29: 618-621.
22. Uusitalo H, Chen E, Pfeiffer N, et al. Switching froma preserved to a preservative-free prostaglandinpreparation in topical glaucoma medication. Acta Ophthalmol. 2010;88: 329-336.
23. Hommer A, Mohammed Ramez O, Burchert M,Kimmich F. IOP-lowering efficacy and tolerabilityof preservative-free tafluprost 0.0015% amongpatients with ocular hypertension or glaucoma.Curr Med Res Opin. 2010;26: 1905-1913.
24. Kahook, MY, Noecker, R Quantitative analysis ofconjunctival goblet cells after chronic applicationof topical drugs. Adv Ther. 2008;25: 743-751.
25. Baudouin C. Detrimental effect of preservativesin eyedrops: Implications for the treatment ofglaucoma. Acta Ophthalmol. 2008;86: 716-726.